9 results about "Demethylating agent" patented technology

This invention discloses a method for preparing raloxifene EP impurity B, comprising the following steps: dissolving 6-methoxy-2-(4-methoxyphenyl)benzothiophene (Ⅰ) as a raw material in solvent one, adding NIS, and then adding a free radical initiator to react and obtain intermediate III; dissolving 4-[2-(1-pyrrolidinyl)ethoxy]benzoate salt (II) in solvent two, adding solvent two or not, and then adding a chlorinating agent to react and generate intermediate IV; dissolving intermediate III in solvent three, adding a Lewis acid, and then adding intermediate IV, and performing a Friedel-Crafts acylation reaction to generate intermediate V; dissolving intermediate V in solvent four, adding a demethylating agent, and generating bisphenol hydroxyl intermediate VI under demethylation conditions; dissolving intermediate VI in solvent five, adding a reducing agent, and generating intermediate VII through a reduction reaction; dissolving intermediate VII in formic acid, stirring, evaporating, and finally lyophilizing to generate the formate target product VIII.

Disclosed herein is a method for enhancing antitumor T cell responses in subjects. The method involves administering to the subject in need thereof a composition comprising a demethylating agent in an amount effective to demethylate STING proteins in the tumor cells. This method is particularly useful in subjects with deficient STING expression in the tumor cells. Therefore, also disclosed is a method for treating a tumor in a subject that involves detecting in a biopsy sample from the subject reduced STING expression, reduced cGAS expression, or a combination thereof; and then administering to the subject a demethylating agent in an amount effective to demethylate STING proteins in the tumor cells. The method can further involve administering to the subject a therapeutically effective amount of a STING agonist. The method can further involve administering to the subject tumor infiltrating lymphocytes (TILs), such as HLA-matched TILs.

The present application relates to a deuterium-labeled psychoactive substance, which has a chemical structural formula as shown in the description.The present application also provides a preparation method of the deuterium-labeled psychoactive substance, which comprises the following steps: (1) removing the methyl group of sufentanil under the action of a demethylating agent to generate a demethylated intermediate; (2) reacting the demethylated intermediate with a deuterated methyl reagent to generate the deuterium-labeled sufentanil.The present application also provides the use of the deuterium-labeled sufentanil in detecting the content of sufentanil in biological samples or environmental samples.

Provided is a method for preparation of a composition comprising activated human CD8+ lymphocytes with phenotype of stem cell-like memory cells and natural killer (NK) lymphocytes. The method entails use of short-term activation of lymphocytes by CD3 / CD28 activating agents followed by treatment with DNA-demethylating agent. The invention also provides a version of the method where addition of a CD3 / CD28 activating agent is made a few days after initiation of CD4+ mediated activation of the CD8+ cells; this step is also disclosed as an improvement of related methods where autologous dendritic cells have been used to activate the lymphocytes. Also provided is a method for treatment of cancer using the cells obtained from the process.

The invention discloses a preparation method and application of a pyridylpiperazine modified quinazolinyl-aryl urea derivative, and the method comprises the following steps: taking 4-chloro-6, 7-dimethoxy quinazoline as a raw material, reacting with 3-nitrobenzylamine hydrochloride to obtain an intermediate 2, adopting a demethylation reagent to remove methyl at the 6-position of a quinazoline ring with high selectivity to obtain the pyridylpiperazine modified quinazolinyl-aryl urea derivative. The preparation method comprises the following steps: firstly, preparing a key intermediate 3, modifying a hydrophilic group pyridyl piperazine unit and a lipophilic group (alkyl with four carbon atoms) on the basis of the intermediate, then reducing, and finally reacting with phenyl isocyanate (or phenyl isocyanate derivative) to obtain a target product. The method is simple, efficient and high in yield, a plurality of compounds in the product obtained by adopting the method show good proliferation inhibition effects on tumor cells of human bladder cancer, osteosarcoma, pancreatic cancer, breast cancer, cervical cancer and the like, and the product is good in water solubility and fat solubility and has the potential to become a tumor molecular targeting drug.

Disclosed herein is a method for enhancing antitumor T cell responses in subjects. The method involves administering to the subject in need thereof a composition comprising a demethylating agent in an amount effective to demethylate STING proteins in the tumor cells. This method is particularly useful in subjects with deficient STING expression in the tumor cells. Therefore, also disclosed is a method for treating a tumor in a subject that involves detecting in a biopsy sample from the subject reduced STING expression, reduced cGAS expression, or a combination thereof; and then administering to the subject a demethylating agent in an amount effective to demethylate STING proteins in the tumor cells. The method can further involve administering to the subject a therapeutically effective amount of a STING agonist. The method can further involve administering to the subject tumor infiltrating lymphocytes (TILs), such as HLA-matched TILs.

This document provides a method for manufacturing herbicides. [Solution] A method is provided that includes reacting a compound of formula I-C with a demethylating agent. TIFF2026136210000117.tif5884 [In the formula, R 1 R is a C1-C4 alkyl or C3-C6 cycloalkyl group; 2 is Cl; R 5 is F, Cl or CH3; and R 6 [is H]

This invention proposes a photo-triggered pyroptosis nanomedicine composition, its preparation method, and its application, belonging to the field of pharmaceutical technology. The nanomedicine composition consists of spherical nanoparticles with a core-shell structure: an outer carrier (bovine serum albumin); a middle photothermal agent (poly(dithiophene-pyrrolopyrroledione); and a core demethylating agent (lipophilic demethylating agent RG108). This invention achieves successful triggering of pyroptosis and a sustained anti-tumor immune cycle with only a single dose and minimal light exposure, significantly improving the response rate of immunotherapy and providing a novel and highly innovative strategy for photo-immunotherapy of tumors.

This invention belongs to the field of biomedicine, specifically relating to a combination drug composition for Ph+ALL and its application. This invention discloses a combination drug composition for Ph+ALL, characterized by comprising a BCL-2 inhibitor, a demethylating agent, and a TKI. The technical solution of this invention expands the chemotherapy-free treatment modality for Ph+ALL, not only enabling patients to achieve rapid and deep remission while observing no unacceptable treatment-related toxicities, but also significantly improving the quality of life of treatment-naïve patients, reducing treatment-related complications, decreasing the consumption of blood products, shortening hospital stays, and significantly reducing medical insurance expenditures.